Andrew White, MD
Allergy & Immunology · San Diego, CANPI 1750352761
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $554,674 of the $752,284 with a category attached, or 73.7%. 52 manufacturers reported payments, led by GSK at 27.3% of the total. Among allergy & immunology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,519 payments — averaging $495.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$206K
- Regeneron Healthcare Solutions, Inc.$125K
- AstraZeneca$116K
- Blueprint Medicines Corporation$112K
- Sanofi$79K
- Optinose US, Inc.$53K
- plus $61K from 46 others
Across 33 payments — averaging $14,209 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$314K
- Sanofi Pasteur Inc.$154K
- Sanofi-aventis U.S. LLC$959
What the payments were for
- Consulting fees$95,00313%
- Speaking & faculty fees$554,67474%
- Travel & lodging$67,6929%
- Food & beverage$34,6445%
- Education$2720%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$752,284 in reported general payments places this provider in the 95th percentile of 426 allergy & immunology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 108 | $414,626 |
| XolairOmalizumab | 92 | $345,050 |
| NucalaMepolizumab | 46 | $175,497 |
| Dupixent SyringeDupilumab | 38 | $144,459 |
| GammaplexImmun Glob G(Igg)/Gly/Iga 0-50 | 21 | $40,735 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 39 | $34,031 |
| Cromolyn Sodium | 56 | $29,322 |
| Spiriva RespimatTiotropium Bromide | 34 | $26,569 |
| XhanceFluticasone Propionate | 18 | $13,697 |
| Breo ElliptaFluticasone/Vilanterol | 28 | $12,101 |
| Wixela InhubFluticasone Propion/Salmeterol | 44 | $11,717 |
| DuleraMometasone/Formoterol | 19 | $9,151 |
| Qvar RedihalerBeclomethasone Dipropionate | 11 | $5,296 |
| BreynaBudesonide/Formoterol Fumarate | 30 | $5,258 |
| Advair DiskusFluticasone Propion/Salmeterol | 16 | $4,535 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Genentech, Inc.Xolair | $2,333 | $345,05092 claims |
| GSKNucala, Trelegy Ellipta, Breo Ellipta | $205,573 | $221,629113 claims |
| Cycle Pharmaceuticals IncCromolyn Sodium | $44 | $29,32256 claims |
| Boehringer IngelheimSpiriva Respimat | $445 | $26,56934 claims |
| Optinose US, Inc.Xhance | $53,427 | $13,69718 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $148 | $5,29611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 426 allergy & immunology providers in California.
Other allergy & immunology in San Diego
- Bob GengSan Diego$3.3M
- Marc RiedlSan Diego$725K
- Katharine WoessnerSan Diego$581K
- Bruce ZurawSan Diego$232K
- Brian StoneSan Diego$146K
- Bruce PrennerSan Diego$129K
- Seema AcevesSan Diego$122K
- Susan LaubachSan Diego$86K
- Harold HoffmanSan Diego$76K
- Alexander GreinerSan Diego$51K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.